digoxin and bisoprolol

Additive pharmacodynamic effects on the cardiac conduction system. Both digoxin and bisoprolol slow atrioventricular (AV) node conduction and reduce heart rate. Digoxin inhibits the sodium-potassium ATPase, increasing vagal tone and prolonging AV nodal refractoriness. Bisoprolol blocks beta-1 adrenergic receptors, further reducing sympathetic drive to the sinus and AV nodes.

Increased risk of bradycardia, AV block, and possibly heart failure exacerbation. Both drugs have negative chronotropic and dromotropic effects, which can lead to symptomatic bradycardia, particularly in patients with conduction abnormalities or those on high doses. Additionally, bisoprolol may mask the tachyarrhythmias that sometimes herald digoxin toxicity, potentially delaying recognition.

Co-prescription is often intentional in heart failure and atrial fibrillation, but requires caution. Monitor heart rate and blood pressure before and after initiating therapy or dose changes. Consider ECG monitoring for patients with underlying conduction disease or at risk of hypokalaemia. Adjust doses as needed; avoid in patients with marked bradycardia or high-degree AV block without a pacemaker. Monitor digoxin levels if renal function changes or signs of toxicity appear.

This interaction is well-established in clinical pharmacology and widely documented. Evidence comes from pharmacological principles, clinical studies, and case reports. It is a common combination in heart failure management, and guidelines recommend careful use.